Cytel Announces Compass®-The Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies
Cytel Inc., recently unveiled Compass, an industrial strength software package for adaptive dose-finding studies based on frequentist or Bayesian methods.
The FDA's recently issued adaptive trial guidelines draft encourages adaptive design use, especially in attempts to identify the optimal dose level.
Cytel has been at the forefront of applying adaptive trials in clinical practice for several years. Compass® has been developed from this experience and knowledge gained by East®, the extensively used adaptive and group sequential software for registration studies. Compass® now extends Cytel's adaptive design software line to include phase 2 dose-finding clinical trials.
Designers of dose ranging studies are challenged to find the correct dose(s) to carry into confirmatory development. The PhRMA Adaptive Dose Response Group has shown that adaptive methods often substantially improve on traditional designs at this crucial best dose determination stage.
Wider use of adaptive trials at this stage was previously inhibited by the lack of validated commercial software. Sponsor statisticians and their regulatory counterparts could only attempt to write their own statistical design code.
The advent of Compass® provides study planners with a workflow for modern dose identification study construction using accepted adaptive methods. The built-in high-speed simulation engine quantifies design option decision-making, while visualizations of the trial characteristics improve understanding amongst both development teams and regulators, too.
A demonstration is replay-able at: http://www.cytel.com/News/Webinars.aspx
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
